Parkwood LLC Has $20.10 Million Stock Holdings in Danaher Corporation $DHR

Key Points

• Parkwood LLC increased its shareholding in Danaher Corporation by 113.8% to a total of 98,036 shares, making it the fund's 16th largest investment.
• A significant number of institutional investors are involved with Danaher, with approximately 79.05% of the stock owned by such investors.
• The stock received varied ratings from analysts, with a consensus price target of $246.35 and the majority rating it as a "Moderate Buy."

Parkwood LLC grew its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 113.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 98,036 shares of the conglomerate's stock after purchasing an additional 52,180 shares during the period. Danaher makes up approximately 1.8% of Parkwood LLC's investment portfolio, making the stock its 16th largest holding. Parkwood LLC's holdings in Danaher were worth $20,097,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of DHR. Heck Capital Advisors LLC acquired a new position in shares of Danaher during the fourth quarter valued at approximately $27,000. GHP Investment Advisors Inc. increased its stake in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the period. Sierra Ocean LLC increased its stake in shares of Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in shares of Danaher during the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its stake in shares of Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 2.2%

Shares of NYSE:DHR traded down $4.39 during mid-day trading on Tuesday, hitting $194.24. The stock had a trading volume of 3,344,891 shares, compared to its average volume of 2,899,976. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market cap of $139.09 billion, a PE ratio of 41.33, a P/E/G ratio of 2.77 and a beta of 0.75. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The company's 50 day moving average is $201.82 and its 200-day moving average is $199.20.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm's quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research note on Tuesday, September 2nd. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Guggenheim reiterated a "buy" rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. UBS Group lowered their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Finally, Barclays restated an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.